CN102026621A - 稳定的药物制剂 - Google Patents

稳定的药物制剂 Download PDF

Info

Publication number
CN102026621A
CN102026621A CN200980117358XA CN200980117358A CN102026621A CN 102026621 A CN102026621 A CN 102026621A CN 200980117358X A CN200980117358X A CN 200980117358XA CN 200980117358 A CN200980117358 A CN 200980117358A CN 102026621 A CN102026621 A CN 102026621A
Authority
CN
China
Prior art keywords
solution
medicament
combination
aqueous pharmaceutical
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980117358XA
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·E·奇普
约瑟夫·C·T·旺
拉卡什米·奈尔
里甘·米勒
巴莱特·E·拉比诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN102026621A publication Critical patent/CN102026621A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980117358XA 2008-05-15 2009-05-08 稳定的药物制剂 Pending CN102026621A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5330108P 2008-05-15 2008-05-15
US61/053,301 2008-05-15
PCT/US2009/043295 WO2009140162A1 (en) 2008-05-15 2009-05-08 Stable pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CN102026621A true CN102026621A (zh) 2011-04-20

Family

ID=40941781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980117358XA Pending CN102026621A (zh) 2008-05-15 2009-05-08 稳定的药物制剂

Country Status (8)

Country Link
US (2) US8183233B2 (https=)
EP (1) EP2288338A1 (https=)
JP (1) JP2011520889A (https=)
CN (1) CN102026621A (https=)
CA (1) CA2722602A1 (https=)
MX (1) MX2010012451A (https=)
TW (1) TW201008594A (https=)
WO (1) WO2009140162A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103330933A (zh) * 2013-04-26 2013-10-02 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN104861043A (zh) * 2014-05-29 2015-08-26 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN106456792A (zh) * 2014-08-20 2017-02-22 株式会社大熊制药 制备含厄他培南的冻干制剂的方法
CN117088974A (zh) * 2023-08-14 2023-11-21 武汉健昊生物科技有限公司 一种抗体保存液

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
BRPI0911048A2 (pt) 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
WO2013078554A1 (en) * 2011-12-02 2013-06-06 University Health Network Compositions of tigecycline and uses thereof
HRP20161703T1 (hr) 2012-11-20 2017-03-10 Fresenius Kabi Usa, Llc Formulacije kaspofungin acetata
IN2014CH00062A (https=) * 2014-01-07 2015-07-10 Hospira Inc
ES2694561T3 (es) * 2015-02-23 2018-12-21 Selectchemie Ag Composición de anidulafungina
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3554474B1 (en) 2016-12-16 2023-12-06 Baxter International Inc. Micafungin compositions
US11968975B2 (en) * 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908614A (en) 1954-08-10 1959-10-13 Glaxo Lab Ltd Use of dextran in freeze-drying process
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
EP0410207B1 (en) 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
JPH051075A (ja) * 1991-06-25 1993-01-08 Lederle Japan Ltd カルバペネム化合物を安定に含有する水溶液
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JPH0769887A (ja) * 1993-07-09 1995-03-14 Takeda Chem Ind Ltd ペネム化合物含有固形組成物、その製造法および剤
JPH0920688A (ja) * 1995-07-01 1997-01-21 Hideyo Yamaguchi 抗菌用剤
SE9803517D0 (sv) * 1998-10-15 1998-10-15 Astra Ab Pharmaceutical preparation
EP1582204B1 (en) 1999-03-03 2013-09-25 Eli Lilly & Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
US7094601B2 (en) 2000-05-16 2006-08-22 The General Hospital Corporation Microinjection of cryoprotectants for preservation of cells
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2006078066A1 (ja) * 2005-01-21 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. 経気道呼吸器感染症治療剤
CN101472562A (zh) 2006-05-12 2009-07-01 陈献 用于静脉刺激性药物的药物组合物
WO2007142212A1 (ja) * 2006-06-08 2007-12-13 Dainippon Sumitomo Pharma Co., Ltd. 製剤組成物
JPWO2008026556A1 (ja) * 2006-08-29 2010-01-21 第一三共株式会社 １−メチルカルバペネム化合物の凍結乾燥製剤
BRPI0720125A2 (pt) 2006-12-06 2014-01-28 Wyeth Corp Método para armazenar uma formulação líquida; método para a preparação de uma formulação líquida; composição; e método para inibir a agregação induzida por manitol de uma proteína em uma formulação líquida.
CA2675602A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103330933A (zh) * 2013-04-26 2013-10-02 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN104861043A (zh) * 2014-05-29 2015-08-26 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN104861043B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN106456792A (zh) * 2014-08-20 2017-02-22 株式会社大熊制药 制备含厄他培南的冻干制剂的方法
CN106456792B (zh) * 2014-08-20 2019-07-26 株式会社大熊制药 制备含厄他培南的冻干制剂的方法
CN117088974A (zh) * 2023-08-14 2023-11-21 武汉健昊生物科技有限公司 一种抗体保存液
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Also Published As

Publication number Publication date
JP2011520889A (ja) 2011-07-21
CA2722602A1 (en) 2009-11-19
TW201008594A (en) 2010-03-01
EP2288338A1 (en) 2011-03-02
WO2009140162A1 (en) 2009-11-19
US8183233B2 (en) 2012-05-22
US20090286764A1 (en) 2009-11-19
MX2010012451A (es) 2010-12-07
US20120207762A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
US8183233B2 (en) Stable pharmaceutical formulations
EP1468697B1 (en) Compositions containing piperacillin and tazobactam useful for injection
CN100396276C (zh) 依普西龙组合物
US6900184B2 (en) Compositions containing pipercillin and tazobactam useful for injection
US6683100B2 (en) Organic compounds
EP3554474B1 (en) Micafungin compositions
EP3906917B1 (en) Formulations of vancomycin with glycerol
WO2002002125A1 (en) Injectable composition
HK1156861A (en) Stable pharmaceutical formulations
WO2023214433A1 (en) Stable parenteral compositions of parecoxib
EP1800664B1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
AU2005201499B2 (en) Premixed formulation of piperacillin sodium and tazobactam sodium injection
HK1069775B (en) Compositions containing piperacillin and tazobactam useful for injection
HK1105808B (en) Pharmaceutical formulations for parenteral administration comprising epothilone
HK1105808A1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156861

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110420

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156861

Country of ref document: HK